Blockade of the OGF-OGFr pathway in diabetic bone

References

• National Diabetes Statistics Report 2017. Centers for Disease Control and Prevention. Atlanta, GA, 2017.
   Google Scholar
• Yang W, Dall TM, Beronjia K, Lin J, Semilla AP, Chakrabarti R, Hogan PF. Economic costs of diabetes in the U.S. in 2017. American Diabetes Association, 2018. Diabetes Care.
   Google Scholar
• Falanga V. Wound healing and its impairment in the diabetic foot. The Lancet. 2005;366:1736–1743. doi:10.1016/S0140-6736(05)67700-8.
   PubMed Web of Science ®Google Scholar
• Hofbauer LC, Brueck CC, Singh SK, Dobnig H. Osteoporosis in patients with diabetes mellitus. J Bone Miner Res. 2007;22:1317–1328. doi:10.1359/jbmr.070510.
   PubMed Web of Science ®Google Scholar
• Shah VN, Carpenter RD, Ferguson VL, Schwartz AV. Bone health in type 1 diabetes. Curr Opin Endocrinol Diabetes Obes. 2018;25:231–236. doi:10.1097/MED.0000000000000421.
   PubMed Web of Science ®Google Scholar
• Hygum K, Starup-Linde J, Harslef T, Vestergaard P, Langdahl BI. Diabetes mellitus, a state of low bone turnover – a systemic review and meta-analysis. Eur J Endocrinol. 2017;176:R137–R157. doi:10.1530/EJE-16-0652.
   PubMed Web of Science ®Google Scholar
• Weber DR, O’Brien KO, Schwartz GJ. Evidence of disordered calcium metabolism in adolescent girls with type 1 diabetes: an observational study using a dual-stable calcium isotope technique. Bone. 2017;105:184–190. doi:10.1016/j.bone.2017.09.001.
   PubMed Web of Science ®Google Scholar
• Motel K, McCabe LR. Streptozotocin, type 1 diabetes severity and bone. Biol Proceed Online. 2009;11:296–315. doi:10.1007/s12575-009-9000-5.
   PubMed Web of Science ®Google Scholar
• Kayal RA, Tsatsas D, Bauer MA, Allen B, Al‐Sebaei MO, Kakar S, Leone CW, Morgan EF, Gerstenfeld LC, Einhorn TA, Graves DT. Diminished bone formation during diabetic fracture healing is related to the premature resorption of cartilage associated with increased osteoclast activity. J Bone Miner Res. 2007;22:560–568. doi:10.1359/jbmr.070115.
   PubMed Web of Science ®Google Scholar
• Lu H, Kraut D, Gerstenfeld LC, Graves DT. Diabetes interferes with the bone formation by affecting the expression of transcription factors that regulate osteoblast differentiation. Endocrinology. 2003;144:346–352. doi:10.1210/en.2002-220072.
   PubMed Web of Science ®Google Scholar
• Almubarak S, Nethercott H, Freeberg M, Beaudon C, Jha A, Jackson W, Marcucio R, Miclau T, Healy K, Bahney C. Tissue engineering strategies for promoting vascularized bone regeneration. Bone. 2015;83:197–209. doi:10.1016/j.bone.2015.11.011.
   PubMed Web of Science ®Google Scholar
• Eimar H, Alebrahim S, Manickam G, Al-Subaie A, Abu-Nada L, Murshed M, Tamimi F. Donepezil regulates energy metabolism and favors bone mass accrual. Bone. 2015;84:131–138. doi:10.1016/j.bone.2015.12.015.
   PubMed Web of Science ®Google Scholar
• Wey A, Cunningham C, Hreha J, Breitbart E, Cottrell J, Ippolito J, Clark D, Lin H, Benevenia J, O’Connor JP, Lin SS, Paglia DN. Local ZnCl2 accelerates fracture healing. J Orthop Res. 2014;32:834–841. doi:10.1002/jor.22593.
   PubMed Web of Science ®Google Scholar
• Negri M, Tonnarini G, D’Alessandro M, Fallucca F. Plasma met-enkephalin in Type I diabetes. Metabolism. 1992;41:460–461. doi:10.1016/0026-0495(92)90200-T.
   PubMed Web of Science ®Google Scholar
• Fallucca F, Tonnarini G, Di Biase N, D’Alessandro M, Negri M. Plasma met-enkephalin levels in diabetic patients: influence of autonomic neuropathy. Metabolism. 1996;4:1065–1068. doi:10.1016/S0026-0495(96)90004-9.
   Google Scholar
• Immonen JA, Zagon IS, McLaughlin PJ. Selective blockade of the OGF-OGFr pathway by naltrexone accelerates fibroblast proliferation and wound healing. Exp Biol Med. 2014;239:300–1309. doi:10.1177/1535370214543061.
   Web of Science ®Google Scholar
• Cheng F, McLaughlin PJ, Verderame MF, Zagon IS. The OGF-OGFr axis utilizes the P16INK4a and P21WAF1/CIP1 pathways to restrict normal cell proliferation. Mol Biol Cell. 2009;20:319–327. doi:10.1091/mbc.e08-07-0681.
   PubMed Web of Science ®Google Scholar
• McLaughlin PJ, Zagon IS. Duration of opioid receptor blockade determines biotherapeutic response. Biochem Pharmacol. 2015;97:236–246. doi:10.1016/j.bcp.2015.06.016.
   PubMed Web of Science ®Google Scholar
• Klocek MS, Sassani JW, McLaughlin PJ, Zagon IS. Topically applied naltrexone restores corneal reepithelialization in diabetic rats. J Ocul Pharmacol Ther. 2007;23:89–102. doi:10.1089/jop.2006.0111.
   PubMed Web of Science ®Google Scholar
• Zagon IS, Sassani JW, Carroll MA, McLaughlin PJ. Topical application of naltrexone facilitates reepithelialization of the cornea in diabetic rabbits. Brain Res Bull. 2010;81:248–255. doi:10.1016/j.brainresbull.2009.10.009.
   PubMed Web of Science ®Google Scholar
• Zagon IS, Sassani JW, McLaughlin PJ. Re-epithelialization of the rat cornea is accelerated by blockade of opioid receptors. Brain Res. 1998;798:254–260. doi:10.1016/S0006-8993(98)00427-2.
   PubMed Web of Science ®Google Scholar
• McLaughlin PJ, Pothering CA, Immonen JA, Zagon IS. Topical treatment with the opioid antagonist naltrexone facilitates closure of full-thickness wounds in diabetic rats. Exp Biol Med. 2011;236:1122–1132. doi:10.1258/ebm.2011.011163.
   Web of Science ®Google Scholar
• McLaughlin PJ, Immonen JA, Zagon IS. Topical naltrexone accelerates full-thickness wound closure in Type 1 diabetic rats by stimulating angiogenesis. Exp Biol Med. 2013;238:733–743. doi:10.1177/1535370213492688.
   Web of Science ®Google Scholar
• Immonen JA, Zagon IS, Lewis GS, McLaughlin PJ. Topical treatment with the opioid antagonist naltrexone accelerates the remodeling phase of full-thickness wound healing in Type 1 diabetic rats. Exp Biol Med. 2013;238:1127–1135. doi:10.1177/1535370213502632.
   Web of Science ®Google Scholar
• McLaughlin PJ, Cain JD, Titunick MB, Sassani JW, Zagon IS. Topical naltrexone is a safe and effective alternative to standard treatment of diabetic wounds. Adv Wound Care. 2017;6:279–288. doi:10.1089/wound.2016.0725.
   Web of Science ®Google Scholar
• Immonen J, Zagon I, McLaughlin P. Topical naltrexone as treatment for type 2 diabetic cutaneous wounds. Adv Wound Care. 2014;3:419–427. doi:10.1089/wound.2014.0543.
   Google Scholar
• Schmitz N, Laverty S, Kraus VB, Aigner T. Basic methods in histopathology of joint tissues. Osteoarthritis Cartilage. 2010;18:S113–S116. doi:10.1016/j.joca.2009.11.014.
   PubMed Web of Science ®Google Scholar
• Erlebacher A, Derynck R. Increased expression of TGF-beta 2 in osteoblasts results in an osteoporosis-like phenotype. J Cell Biol. 1996;132:195–210.
   PubMed Web of Science ®Google Scholar
• Schneider CA, Rasband WS, Eliceiri KW. NIH image to imageJ: 25 years of image analysis. Nat Methods. 2012;9:671–675. doi:10.1038/nmeth.2089.
   PubMed Web of Science ®Google Scholar
• Lloyd SA, Lang CH, Zhang Y, Paul EM, Laufenberg LJ, Lewis GS, Donahue HJ. Interdependence of muscle atrophy and bone loss induced by mechanical unloading. J Bone Miner Res. 2014;29:1118–1130. doi:10.1002/jbmr.2113.
   PubMed Web of Science ®Google Scholar
• Bouxsein M, Boyd S, Christiansen B, Guldberg R, Jepsen K, Muller R. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res. 2010;25:1468–1486. doi:10.1002/jbmr.141.
   PubMed Web of Science ®Google Scholar
• Adami S. Bone health in diabetes: considerations for clinical management. Curr Med Res Opin. 2009;25:1057–1072. doi:10.1185/03007990902801147.
   PubMed Web of Science ®Google Scholar
• Räkel A, Sheehy O, Rahme E, LeLorier J. Osteoporosis among patients with type 1 and type 2 diabetes. Diabetes Metab. 2008;34:193–205. doi:10.1016/j.diabet.2007.10.008.
   PubMed Web of Science ®Google Scholar
• Rubin MR, Patsch JM. Assessment of bone turnover and bone quality in type 2 diabetic bone disease: current concepts and future directions. Bone Res. 2016;4:16001. doi:10.1038/boneres.2016.1.
   PubMed Web of Science ®Google Scholar
• Jiao H, Xiao E, Graves DT. Diabetes and its effect on bone and fracture healing. Curr Osteoporo. Rep. 2015;13:327–335. doi:10.1007/s11914-015-0286-8.
   PubMed Web of Science ®Google Scholar
• Hamada Y, Kitazawa S, Kitazawa R, Fujii H, Kasuga M, Fukagawa M. Histomorphometric analysis of diabetic osteopenia in streptozotocin-induced diabetic mice: possible role of oxidative stress. Bone. 2006;40:1408–1414. doi:10.1016/j.bone.2006.12.057.
   PubMed Web of Science ®Google Scholar
• Erdal N, Gurgul S, Demirel C, Yildiz A. The effect of insulin therapy on biomechanical deterioration in streptozotocin (STZ)-induced type 1 diabetes mellitus in rats. Diabetes Res Clin Pract. 2012;97:461–467. doi:10.1016/j.diabres.2012.03.005.
   PubMed Web of Science ®Google Scholar